Immune and nonimmune causes of low recovery from leukodepleted platelet transfusions: a prospective study.
Alloantibodies against HLA antigens can be reduced by applying leukodepletion to transfusions. Because the importance of immunological and nonimmunological causes of poor platelet transfusion results using leukodepleted transfusions is not clear, we conducted a prospective study in an unselected patient population receiving leukodepleted transfusions. In 97 patients with hematological malignancies, 181 random leukodepleted platelet transfusions were studied for immunological causes of poor platelet transfusion results by calculating the odds ratio of four different screening tests for a low platelet recovery. Nonimmune causes were also studied by calculating the odds ratio of the most prevalent nonimmune causes for a low platelet recovery. No single screening test showed an association with recovery after 1 and 16 h following a platelet transfusion. The combination of a positive enzyme-linked immunosorbent assay (ELISA) and platelet immunofluorescence test (PIFT) or a combination of a positive lymphocyte immunofluorescence test (LIFT) and PIFT, demonstrating an association with a low platelet recovery after 16 h, was present in 2% of all platelet transfusions. Of nonimmune causes, splenomegaly and storage time of platelets for more than 3 days were associated with low platelet recovery after 1 h and 16 h of being present in 29% and 47% of all platelet transfusions, respectively. Immunological causes account for a small proportion of poor platelet transfusion results compared to nonimmunological causes in a nonselected patient population receiving leukodepleted transfusions.
Levin
M-D
MD
Department of Hematology, Erasmus Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. levin@xs4all.nl
de Veld
J C
JC
van der Holt
B
B
van 't Veer
M B
MB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007938:Leukemia / Q000097:blood / Q000628:therapy*; D008223:Lymphoma / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects*; D011446:Prospective Studies; D012044:Regression Analysis